Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthon Pharmaceuticals Inc.

Division of Synthon BV
www.synthon.com/us

Latest From Synthon Pharmaceuticals Inc.

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

ImmunoOncology Deals

Teva Catches A Break On Copaxone 40mg, But For How Long?

An FDA warning letter cites deficiencies at the Pfizer-owned manufacturing facility poised to produce a Momenta/Sandoz generic competitor. It’s unclear how long Pfizer might take to resolve the violations, which include particulates in finished products.

Generic Drugs Manufacturing

Teva Catches A Break On Copaxone 40mg, But For How Long?

An FDA warning letter cites deficiencies at the Pfizer-owned manufacturing facility poised to produce a Momenta/Sandoz generic competitor. It’s unclear how long Pfizer might take to resolve the violations, which include particulates in finished products.

Generic Drugs Manufacturing

Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February

Teva is seeking injunction to block generic entry after court rules four patents on the three-times-a-week dosage are invalid; analysts expect launch soon after FDA approves an ANDA, with Sandoz/Momenta generic the likely leader.

BioPharmaceutical Policy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Synthon BV
  • Senior Management
  • Rudy Mareel, CEO
  • Contact Info
  • Synthon Pharmaceuticals Inc.
    Phone: (919) 493-6006
    9000 Development Dr.
    P.O. Box 110487 Research Triangle Park, NC 27709
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register